While the use of PD-1/PD-L1 inhibitors as single agents has shown disappointing efficacy in R/R DLBCL, with CR rates ranging from 0% to 9% [130,131], or as a consolidation therapy following ASCT or CAR-T [132,133,134], they have shown promise in combination therapies. The gene discussed is PDCD1; the disease is diffuse large B-cell lymphoma.